Related Experiment Video
Updated: Jun 4, 2025
Chronic Salmonella Infection Induced Intestinal Fibrosis
Published on: September 22, 2019
Risk of comorbidity of autoimmune liver disease in patients with inflammatory bowel disease: A single-center
Meng Yuan Zhang1, Tian Ming Xu1, Ying Hao Sun1
1Department of Gastroenterology, Peking Union Medical College Hospital, Beijing, China.
Insights
Patients with inflammatory bowel disease (IBD) face a higher risk of developing autoimmune hepatitis (AIH) and primary sclerosing cholangitis (PSC). However, these co-occurring conditions do not significantly increase hospitalization costs for IBD patients.
Area of Science:
- Gastroenterology
- Hepatology
- Immunology
Background:
- Inflammatory bowel disease (IBD) encompasses chronic conditions like Crohn's disease and ulcerative colitis.
- Autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC) are distinct immune-mediated liver diseases.
- Understanding the interplay between IBD and these liver conditions is crucial for comprehensive patient care.
Purpose of the Study:
- To determine the prevalence of AIH, PBC, and PSC in patients with IBD.
- To assess the impact of these liver diseases as comorbidities on the hospitalization burden in IBD patients.
Main Methods:
- Retrospective analysis of inpatient data from Peking Union Medical College Hospital (1998-2021).
- Comparison of AIH, PBC, and PSC risk between IBD and non-IBD patient cohorts using odds ratios (OR) and 95% confidence intervals (CI).
- Evaluation of medical costs and length of hospitalization for IBD patients with and without AIH, PBC, or PSC.
Main Results:
- IBD patients exhibited a significantly elevated risk for AIH (OR 4.87) and PSC (OR 112.28) compared to non-IBD individuals.
- No significant difference in PBC risk was observed between IBD and non-IBD groups (OR 1.60).
- The presence of AIH, PBC, or PSC did not significantly alter the average medical cost per hospitalization for IBD patients.
Conclusions:
- Patients with IBD have an increased susceptibility to developing AIH and PSC.
- Comorbid AIH, PBC, or PSC does not substantially impact the average hospitalization costs in IBD patients.
- Further research may explore the mechanisms underlying the increased risk of AIH and PSC in IBD.
Objective:
To investigate the prevalence of autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC), and the impact of comorbidity of AIH, PBC, and PSC on hospitalization burden in patients with inflammatory bowel disease (IBD).
Methods:
Inpatients admitted to Peking Union Medical College Hospital from January 1, 1998 to December 31, 2021 were included. Odds ratio (OR) and the corresponding 95% confidence interval (CI) were calculated to compare the risk of AIH, PBC, and PSC between IBD and non-IBD patients. Medical cost and length of hospitalization were compared between IBD patients with and without AIH, PBC, or PSC.
Results:
Among the included 858 967 inpatients, there were 3059 patients with IBD. Additionally, there were 117 patients with AIH, 879 patients with PBC, and 35 patients with PSC, regardless of having IBD or not. Patients with IBD had a significantly higher risk of AIH (OR 4.87, 95% CI 1.20-19.71, p = 0.03) and PSC (OR 112.28, 95% CI 53.88-233.98, p < 0.01) than those without IBD. While there was no significant difference in the risk of PBC between patients with and without IBD (OR 1.60, 95% CI 0.67-3.86, p = 0.29). The medical cost of each hospitalization did not differ between IBD patients with and without AIH, PBC, or PSC.
Conclusions:
IBD patients had a higher risk of AIH and PSC. Comorbidity of AIH, PBC, or PSC has no significant effect on the average cost of each hospitalization in IBD patients.
More Related Videos
Related Concept Videos
01:17Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
01:17Irritable Bowel Syndrome I: Introduction
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...